Clicky

Pacira Pharmaceuticals, Inc.(PCRX) News

Date Title
May 15 Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
Apr 21 DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
Apr 17 Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
Apr 15 Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth?
Apr 11 Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 10 The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
Apr 9 Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
Apr 9 Pacira price target raised to $28 from $25 at Truist
Apr 8 PCRX Stock Soars on Exparel Patent Settlement With Generic Players
Apr 7 Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
Mar 14 Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
Mar 14 DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences
Feb 20 Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term
Feb 20 Pacira to Report 2024 Financial Results on Thursday February 27, 2025
Feb 11 Best Value Stocks to Buy for February 11th
Jan 2 Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sep 26 Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Sep 25 DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
Jul 30 Pacira: Q2 Earnings Snapshot
Jul 30 Pacira BioSciences Reports Second Quarter 2024 Financial Results